Insulin Aspart

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

Adults with diabetes who use a smart pen for both basal and bolus insulin delivery have a reduction in time in range with each injection they miss over a 14-day period, according to data published in Diabetes Care.

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to topline results from a phase 3a trial.

Fast-acting insulin aspart delivered through a hybrid closed-loop insulin delivery system provided similar glycemic outcomes as standard insulin aspart for young children with type 1 diabetes, according to study data.

Novo Nordisk is the latest company to announce a large reduction in insulin prices as it stated it will cut prices for multiple insulin products by up to 75% in 2024.

Fast-acting insulin aspart provides similar time in range as insulin aspart for adults with type 1 diabetes engaging in moderate- or high-intensity exercise, according to study findings published in Diabetes Technology & Therapeutics.

Walmart announced that insulin aspart injections are now available through its private ReliOn brand, with doses discounted from 58% to 75% off other insulin products. The announcement was the top story in endocrinology last week.

Walmart announced it will partner with Novo Nordisk to launch a first-ever private brand analog insulin, retailing up to 75% off the cash price of branded insulin products, according to a press release.

ADO09, a co-formulation of pramlintide and insulin A21G, was associated with better glucose levels, improved time in range and more weight loss among people with type 1 diabetes compared with insulin aspart, according to a presenter.

A follow-on therapy to insulin aspart was shown to be safe and effective for pump use among adults with type 1 diabetes, with no increased incidence of unexplained hypoglycemia when compared with the reference product, according to findings from an open-label crossover study published in Diabetes Technology & Therapeutics.